GlassScriptPhysician profile
Luis J Forastieri
NPI 1902808553
$5,720.81
in general payments reported to CMS, 2019-2025
22 companies · $2,060 in 2025
The $2,060 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $282 · 2021: $555 · 2022: $854 · 2023: $613 · 2024: $910 · 2025: $2,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008 · Consulting Fee: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.20 |
| Consulting Fee | $1,575.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,374.81 | 2021-2025 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $509.29 | 2019-2025 | Emgality, Kisunla |
| Amneal Pharmaceuticals LLC | $356.97 | 2019-2025 | Rytary, Crexont |
| E.R. Squibb & Sons, L.L.C. | $355.64 | 2020-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $333.23 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $255.75 | 2019-2025 | |
| Biogen, INC. | $235.98 | 2021-2023 | Vumerity, Tysabri, Plegridy |
| Genzyme Corporation | $179.49 | 2021-2023 | |
| Eisai INC. | $178.91 | 2023-2024 | |
| Pbg Puerto Rico LLC | $157.38 | 2023-2025 | |
| Ucb, INC. | $133.24 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $109.91 | 2023-2025 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $100.00 | 2022 | |
| Acadia Pharmaceuticals INC | $82.55 | 2021-2024 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $71.45 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $67.86 | 2022-2025 | Ultomiris |
| Emd Serono, INC. | $51.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $49.70 | 2021 | |
| Amgen INC. | $48.12 | 2021-2022 | |
| Genentech USA, INC. | $24.95 | 2022 | |
| Allergan, INC. | $24.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.84 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Forastieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.